Page last updated: 2024-11-04

terazosin and Obesity

terazosin has been researched along with Obesity in 2 studies

Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alonso-Galicia, M1
Brands, MW1
Zappe, DH1
Hall, JE1
Antic, V1
Kiener-Belforti, F1
Tempini, A1
Van Vliet, BN1
Montani, JP1

Other Studies

2 other studies available for terazosin and Obesity

ArticleYear
Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity.
    Hypertension (Dallas, Tex. : 1979), 1996, Volume: 28, Issue:6

    Topics: Adrenergic alpha-Antagonists; Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds;

1996
Role of the sympathetic nervous system during the development of obesity-induced hypertension in rabbits.
    American journal of hypertension, 2000, Volume: 13, Issue:5 Pt 1

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Blood Pressure D

2000